Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of an in-vitro test protocol using a three-dimensional human buccal oral mucosal model to assess the oral medical devices.

Toxicology in vitro : an international journal published in association with BIBRA·2026
Same author

A Standard Herbal Formula, CGAC, Attenuates Bone Loss by Normalizing Low-Bone Turnover Stagnation in an Orchiectomy-Induced Mouse Model.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Nationwide population based epidemiological characteristics of complex regional pain syndrome in South Korea.

Scientific reports·2026
Same author

[Surveillance Report of Imported SARS-CoV-2 Variants at Incheon International Airport and Incheon Port (February 15, 2021-March 2023)].

Jugan geon-gang gwa jilbyeong·2025
Same author

[A Brief Report of COVID-19 Test Results of Overseas Entrants to Korea as Requested by National Incheon Airport Quarantine Station in 2022].

Jugan geon-gang gwa jilbyeong·2025
Same author

[Surveillance and Outbreak Status of SARS-CoV-2 Originated from China].

Jugan geon-gang gwa jilbyeong·2025

Related Experiment Video

Updated: Jun 27, 2026

Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules
11:13

Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules

Published on: August 19, 2015

Functionally gradient chitosan/hydroxyapatite composite scaffolds for controlled drug release.

Shu-Hua Teng1, Eun-Jung Lee, Peng Wang

  • 1Department of Materials Science and Engineering, Seoul National University, Seoul 151-744, Korea.

Journal of Biomedical Materials Research. Part B, Applied Biomaterials
|December 17, 2008
PubMed
Summary

This study developed chitosan/hydroxyapatite scaffolds for controlled drug delivery. The gradient structure effectively regulated drug release, showing potential for tissue regeneration and bioactive molecule delivery.

More Related Videos

Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications
05:26

Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications

Published on: April 13, 2022

A Facile and Eco-friendly Route to Fabricate Poly(Lactic Acid) Scaffolds with Graded Pore Size
13:46

A Facile and Eco-friendly Route to Fabricate Poly(Lactic Acid) Scaffolds with Graded Pore Size

Published on: October 17, 2016

Related Experiment Videos

Last Updated: Jun 27, 2026

Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules
11:13

Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules

Published on: August 19, 2015

Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications
05:26

Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications

Published on: April 13, 2022

A Facile and Eco-friendly Route to Fabricate Poly(Lactic Acid) Scaffolds with Graded Pore Size
13:46

A Facile and Eco-friendly Route to Fabricate Poly(Lactic Acid) Scaffolds with Graded Pore Size

Published on: October 17, 2016

Area of Science:

  • Biomaterials Science
  • Drug Delivery Systems
  • Tissue Engineering

Background:

  • Chitosan/hydroxyapatite (HA) composites offer potential for controlled drug delivery.
  • Developing functional scaffolds with gradient structures is key for regulating drug release kinetics.

Purpose of the Study:

  • To explore chitosan/HA composites as controlled drug delivery systems.
  • To create functional scaffolds with a gradient of structure and drug concentration.
  • To investigate the drug release profile of these scaffolds for tissue regeneration applications.

Main Methods:

  • Preparation of a porous chitosan/HA composite scaffold.
  • Impregnation of tetracycline hydrochloride (TCH) as a model drug.
  • Coating with drug-free chitosan/HA layers to create drug concentration gradients.
  • In vitro drug release testing.

Main Results:

  • Scaffold pore size was dependent on HA content (40-250 microm).
  • Outer drug-free layers significantly reduced initial drug burst and extended release.
  • Successive dense layers provided sustained drug release without initial burst.

Conclusions:

  • Hybrid chitosan/HA scaffolds effectively regulate drug release.
  • These scaffolds are capable of serving as temporary drug carriers in tissue regeneration.
  • Potential applications include delivery of bioactive molecules like growth factors.